Skip to main content
. 2017 Nov 22;2017(11):CD012216. doi: 10.1002/14651858.CD012216.pub2

NCT01638949.

Trial name or title Multi‐modal Neuroimaging in Alzheimer's Disease (IMAP+)
Target condition and reference standard(s) Cognitive decline over three years of follow‐up, reference standard not specified
Index and comparator tests 18F‐florbetapir
Starting date 2012
Contact information Vincent de La Sayette, University Hospital, Caen
Notes